STOCK TITAN

HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

HUTCHMED (HCM) reported preclinical results for HMPL-A830 at the EORTC-NCI-AACR cancer therapeutics conference, including findings from tumor cell lines and mouse models.

The candidate pairs an EGFR-targeting antibody with a KRAS inhibitor. In lab tests, the inhibitor blocked both the active and inactive states of KRAS and inhibited growth across 55 tumor cell lines with diverse KRAS alterations. In EGFR-positive mouse tumor models with KRAS alterations, HMPL-A830 showed dose-dependent antitumor activity and produced more durable tumor regressions than KRAS G12C inhibitors.

An ongoing global Phase I trial is evaluating the candidate in patients with unresectable, advanced, or metastatic solid tumors. A GSK subsidiary holds exclusive development and commercialization rights outside Mainland China, Hong Kong, Macau and Taiwan under a September 2026 agreement.

Loading...
Loading translation...
9 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

How the balance works

Positive

  • Moderate pointExclusive license agreement gives a GSK subsidiary development and commercialization rights outside Mainland China, Hong Kong, Macau and Taiwan
  • Minor pointMouse tumor regressions lasted longer with HMPL-A830 than with KRAS G12C inhibitors
  • Minor pointGrowth inhibition extended across 55 tumor cell lines with diverse KRAS alterations
  • Minor pointAntitumor activity in mice was dose-dependent in EGFR-positive tumor models with KRAS alterations
  • Minor pointMouse-model activity exceeded that of the unconjugated antibody, tested pan-RAS inhibitor regimens and a TROP2-targeted antibody-drug conjugate
4 minor points
  • Minor pointKRAS inhibition covered both active and inactive states in lab tests
  • Minor pointEGFR/KRAS signaling inhibition was greater and lasted longer than with the unconjugated antibody
  • Minor pointDrug-to-antibody ratio remained stable in mouse, monkey and human plasma in preclinical analyses
  • Minor pointLab testing showed rapid uptake into EGFR-positive cells and killing of neighboring EGFR-negative tumor cells

Negative

  • None.

News Explained

The Phase Ia trial is ongoing; under the September 2026 agreement, HUTCHMED’s subsidiary is responsible for global Phase I development, while GSK’s subsidiary is responsible for later development and commercialization outside Mainland China, Hong Kong, Macau and Taiwan.

Key Figures

Tumor cell lines tested: 55 tumor cell lines
Tumor cell lines tested
55 tumor cell lines
In vitro profiling across lines harboring diverse KRAS alterations

Key Terms

kras, adcc, pk/pd
3 terms
kras medical
"a highly selective and potent KRAS small molecule inhibitor payload"
KRAS is a gene that makes a protein acting like a switch to control cell growth; certain changes (mutations) can lock that switch on and drive uncontrolled cell multiplication, which is a common cause of many cancers. Investors care because drugs or tests targeting KRAS mutations can create large markets or avoidable risks depending on trial results and regulatory decisions, much like a key product feature deciding a gadget’s commercial success.
adcc medical
"robust antibody-dependent cellular cytotoxicity (ADCC) activity"
Antibody-dependent cellular cytotoxicity (ADCC) is an immune mechanism in which immune effector cells recognize and kill a target cell that has antibodies bound to antigens on its surface. Effector cells—commonly natural killer (NK) cells, macrophages or neutrophils—use Fc receptors to bind the antibody’s Fc region, become activated, and release cytotoxic molecules or trigger phagocytosis that leads to death of the antibody-coated cell. In drug-development and regulatory contexts, ADCC is a measurable function of therapeutic antibodies and can be enhanced or reduced by changes in an antibody’s Fc region; ADCC is distinct from complement-mediated cytotoxicity, which relies on the complement system rather than cellular Fc receptors.
pk/pd medical
"Pharmacokinetic and pharmacodynamic (PK/PD) analyses confirmed"
PK/PD stands for pharmacokinetics and pharmacodynamics: PK describes how a drug moves through the body — how it is absorbed, distributed, broken down and eliminated — while PD describes the drug’s effects on the body and how those effects change with dose. For investors, strong PK/PD data help predict whether a drug can be dosed safely and effectively, shape clinical trial success, regulatory approval chances and commercial potential, much like knowing both delivery speed and the strength of a message before choosing a shipping method.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

— A novel EGFR-directed ATTC with a potent pan-KRAS payload designed to overcome resistance and systemic toxicity associated with EGFR/KRAS inhibition —

— Broad-spectrum activity across multiple KRAS mutations, combining inhibition of both ON and OFF states to intercept adaptive resistance —

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Nov. 18, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces preclinical data for HMPL-A830 presented at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics, held on November 18–20, 2026, in Barcelona, Spain. HMPL-A830 is a first-in-class Antibody-Targeted Therapy Conjugate (“ATTC”) drug candidate comprises a highly selective and potent KRAS small molecule inhibitor payload conjugated to an anti‑epidermal growth factor receptor (“EGFR”) antibody.

RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. While recent targeted therapies have validated KRAS (the most dominant RAS isoform) as a viable therapeutic target, significant clinical gaps remain, including safety limitations and disease progression driven by acquired resistance, often mediated by upstream receptor tyrosine kinase upregulation. HMPL-A830 is designed to address this unmet need by delivering a KRAS inhibitor directly to EGFR-expressing tumors, while simultaneously blocking EGFR and KRAS signaling to enhance efficacy, durability, and tolerability.

In vitro profiling demonstrated that its pan-KRAS payload exhibits a dual-action mechanism, simultaneously blocking both KRAS “ON” (GTP-RAF1 binding) and “OFF” (GDP-to-GTP exchange) activities. Potent antiproliferative activity was observed across a broad panel of 55 tumor cell lines harboring diverse KRAS alterations, including G12C, G12D, G12V and G13D mutations, as well as wild-type amplification. HMPL-A830 exhibited high binding affinity and rapid internalization into EGFR-positive cells. It also demonstrated a strong bystander killing effect, effectively eliminating neighboring EGFR-negative tumor cells, while maintaining robust antibody-dependent cellular cytotoxicity (ADCC) activity.

In mouse models, HMPL-A830 showed dose-dependent and robust antitumor efficacy across various EGFR-positive tumor models harboring KRAS alterations. HMPL-A830 achieved more durable tumor regressions than KRAS G12C inhibitors and outperformed several comparative regimens, including its unconjugated antibody, a pan-RAS inhibitor (administered alone or in combination with cetuximab), and a TROP2-targeted Topo I-inhibitor antibody-drug conjugate. Pharmacokinetic and pharmacodynamic (PK/PD) analyses confirmed a stronger and more sustained inhibition of EGFR/KRAS downstream signaling than the naked antibody, alongside a stable drug-to-antibody ratio (DAR) maintained in mouse, monkey, and human plasma.

In September 2026, HUTCHMED Limited (a subsidiary of the Company) entered into an exclusive development and license agreement with a subsidiary of GSK plc (“GSK”), granting the GSK subsidiary worldwide rights excluding Mainland China, Hong Kong, Macau and Taiwan to develop and commercialize HMPL-A830. HUTCHMED Limited is responsible for the global Phase I development program of HMPL-A830. The GSK subsidiary will be responsible for all subsequent clinical development and commercialization activities outside of Mainland China, Hong Kong, Macau and Taiwan. 

The Phase Ia part of an ongoing global Phase I trial is currently evaluating HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors (NCT07718581).

About HUTCHMED ATTCs

HUTCHMED’s ATTCs represent a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payload platforms to deliver dual mechanisms of action. Unlike traditional cytotoxin-based antibody-drug conjugates, ATTCs combine targeted therapies to achieve synergistic anti-tumor activity and durable responses in preclinical models, outperforming standalone antibody or small-molecule inhibitor components in both efficacy and safety.

Built on over 20 years of targeted therapy expertise, the ATTC platforms enable development of drug candidates across diverse cancer types. By leveraging antibody-guided delivery and tumor-specific payload release, ATTCs improve accessibility to tumors and reduce off-tumor toxicity. This may overcome the on-target, off-tumor toxicity limitations of systemically-delivered small molecule inhibitors, which in turn could ensure safer long-term use and support combinations with chemotherapy and immunotherapy in earlier-line treatments.

About KRAS

RAS mutations represent one of the most prevalent and well-established drivers in human oncology, driving the progression and aggressive pathology of multiple solid tumors. KRAS, the most dominant RAS isoform, is mutated in approximately 44% of colorectal cancer (“CRC”), 34% of lung adenocarcinoma and up to 89% of pancreatic ductal adenocarcinoma (“PDAC”) patients.1 KRAS regulates key downstream pathways, including RAS/MAPK and PI3K/AKT/mTOR, to drive cell differentiation, proliferation, and survival.

While recent targeted therapies have validated KRAS as a viable therapeutic target, significant clinical gaps persist, particularly for patients with non-G12C mutations. Most patients eventually experience disease progression driven by acquired resistance, largely fueled by upstream receptor tyrosine kinase upregulation and secondary KRAS alterations. Beyond mutation coverage, systemic delivery of pan-KRAS and pan-RAS inhibitors is associated with on-target toxicities, such as dermatological toxicity reflecting RAS pathway inhibition in normal tissue. These present challenges for dosing, long-term tolerability, and combination with cytotoxic chemotherapy or immunotherapy backbones that constitute frontline standard-of-care.

About EGFR

EGFR is a widely expressed receptor tyrosine kinase and established driver of tumor cell proliferation, survival, and disease progression across multiple solid tumors, including CRC, PDAC, and non-small cell lung cancer (“NSCLC”). Signaling through EGFR activates the downstream RAS/MAPK and PI3K/AKT/mTOR pathways, positioning the receptor immediately upstream of KRAS. EGFR has also emerged as a key mediator of resistance to KRAS-targeted therapies, particularly in CRC, where adaptive feedback and increased upstream EGFR signaling reactivate the MAPK pathway and limit the depth and durability of KRAS inhibition. Together, these provide a strong rationale for the dual targeting of EGFR and KRAS, not only in CRC but also additional indications such as PDAC and NSCLC.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including, without limitation, statements concerning HUTCHMED’s future plans and prospects, its expectations regarding the therapeutic potential of HMPL-A830 and other drug candidates from the ATTC platform and the further development of HMPL-A830 and other drug candidates from the ATTC platform in this and other indications, as well as the safety, efficacy, tolerability, scalability or combinability of all candidates from the ATTC platform. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the amount and timely receipt of the considerations; satisfaction of the conditions precedent to the consummation of the proposed transactions (including the ability of the parties to secure regulatory approvals on the terms expected, at all or in a timely manner); the ability of the parties to complete the proposed transactions; the continued sufficiency of preclinical and clinical data to support development and approval of the ATTC-based R&D candidates in China, the United States and other jurisdictions; their potential to gain clinical trial approvals from regulatory authorities; the efficacy and safety profile of HMPL-A830 and other drug candidates from the ATTC platform; the timing and outcome of clinical studies and the sufficiency of clinical data to support an new drug application submission of HMPL-A830 and other drug candidates from the ATTC platform in China, the United States or other jurisdictions; its potential to gain approvals from regulatory authorities on an expedited basis or at all; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials or the regulatory pathway for the ATTC candidates; HUTCHMED or GSK’s ability to fund, implement and complete its further clinical development and commercialization plans for HMPL-A830 and other drug candidates from the ATTC platform and the timing of these events. In addition, when or if used herein, the words and phrases “aims,” “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “on track,” “predicts,” “plans,” “potential,” “promising,” “should,” “to be,” “will,” and similar expressions and their variants, as they relate to HUTCHMED may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although HUTCHMED believes the expectations reflected in such forward-looking statements are reasonable, HUTCHMED can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied HUTCHMED’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, assumptions regarding the safety, efficacy, supply, continued regulatory approval of these therapeutics, and in some cases connected to the risks of the use of other drug products as combination therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries+852 2121 8200 / ir@hutch-med.com
  
Media Enquiries 
FTI Consulting –+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper+44 7771 913 902 (Mobile) / +44 7779 436 689 (Mobile)
Brunswick – Zhou Yi+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
  
Panmure LiberumNominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden+44 20 7886 2500
  
CavendishJoint Broker
Geoff Nash / Nigel Birks+44 20 7220 0500
  
Deutsche NumisJoint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith+44 20 7260 1000

_______________
REFERENCES
1  Singhal A, Li BT & O’Reilly EM. Targeting KRAS in cancer. Nat Med 30, 969–983 (2024). DOI: 10.1038/s41591-024-02903-0


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did HUTCHMED's preclinical tests of HMPL-A830 show?

HMPL-A830 inhibited growth across 55 tumor cell lines with diverse KRAS alterations and produced longer-lasting tumor regressions than KRAS G12C inhibitors in mouse models. The cell-line panel included G12C, G12D, G12V and G13D mutations as well as amplification of non-mutated KRAS.

What clinical trial is HUTCHMED running for HMPL-A830?

HMPL-A830 is being evaluated in the Phase Ia portion of a global Phase I trial (NCT07718581) in patients with unresectable, advanced, or metastatic solid tumors.

How are HUTCHMED and GSK dividing responsibility for HMPL-A830 development?

A HUTCHMED subsidiary is responsible for global Phase I development, while the GSK subsidiary is responsible for subsequent clinical development and commercialization outside Mainland China, Hong Kong, Macau and Taiwan.

Keep reading